Bayer confirms outlook, acquires nutrition firm

Bayer reported a 17.8% fall in third-quarter net income, to €528 million ($682.2 million) on sales 11.5% higher, at €9.67 billion. Ebitda before special items improved 2.2%, to €1.85 billion. Net income was down because of special charges, particularly for legal claims and restructuring. The company, meanwhile, confirmed earlier forecasts for the whole of 2012. Dekkers: Quarterly sales good all around. Condon: Safeguarding harvests is a major issue. “The upward trend in our life-science businesses, Bayer HealthCare and Bayer CropScience...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers